{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"retatrutide-tirzepatide","title":"Retatrutide vs Tirzepatide: Human Trial Data on Weight Loss and Load Reduction","body":"## What's breaking down\n\nExcess body weight increases compressive forces across the spine, hips, knees and feet. Each extra pound of body mass adds roughly 4 pounds of load to the lumbar spine during walking. When body weight stays elevated, mechanical stress outpaces natural repair in load-bearing tissues. Both compounds are studied for effects on body weight through GLP-1 and related pathways; any benefit to joints or spine would come from reduced load rather than direct tissue regeneration.\n\n## Why Retatrutide might help you\n\n1. What keeps failing: Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\n2. What Retatrutide is studied to do: Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\n3. Therefore for you: If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\n\n## Why Tirzepatide might help you\n\n1. What keeps failing: Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\n2. What Tirzepatide is studied to do: Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\n3. Therefore for you: If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\n\n## How these fit together\n\nEach compound above targets a different degeneration layer. Together they are a stack — not five copies of the same mechanism.\n- Retatrutide → metabolic load / body weight\n- Tirzepatide → metabolic load / body weight\n\n## What the evidence actually shows\n\nHuman phase 2 and phase 3 trials (human tier) show both compounds produce substantial weight loss. In one retatrutide trial, the 12 mg dose produced mean weight loss of 24.2% at 48 weeks versus 2.1% on placebo. In the SURMOUNT-1 tirzepatide trial, 15 mg produced mean weight loss of 20.9% at 72 weeks versus 3.1% on placebo. Later retatrutide phase 3 data (TRIUMPH-1) reported 28.3% mean loss at 80 weeks on 12 mg. These are percentage changes from baseline body weight in adults with obesity or overweight; results are dose-dependent and gastrointestinal side effects were common during escalation. No head-to-head trials exist yet. All data are from randomized controlled trials published in NEJM and company reports.\n\n## What scientists say\n\nPublished trial authors note the weight reductions exceed those seen with earlier GLP-1 agents and approach levels associated with bariatric surgery in some participants. Reductions in waist circumference, blood pressure and lipids were also observed alongside weight change. Researchers emphasize these are short-to-medium term findings (up to 104 weeks in extensions) and longer-term maintenance and safety data are still being collected.\n\n## What people say on Reddit\n\nAnecdotal reports (anecdotal tier) describe users switching between the two, with some noting stronger appetite suppression on tirzepatide and others preferring retatrutide for perceived energy or easier protein intake. Individual losses of 50–100 lb are mentioned after months of use, but experiences vary widely and many discuss side effects or dose titration challenges. These are self-reported posts from r/RetatrutideTrial, r/Mounjaro and similar communities.\n\n## What people say on X\n\nPublic posts on X are limited in the searched results; available mentions largely repeat trial headlines or user interest in upcoming approvals rather than detailed personal outcomes.\n\n## What we do not know\n\nDirect comparative efficacy, long-term joint or spine outcomes, effects on specific degenerative conditions, and durability of weight loss after discontinuation remain unknown. No human data link either compound to direct cartilage or disc repair independent of weight change.\n\n## Safety and limits\n\nBoth compounds show gastrointestinal adverse events that are mostly mild to moderate and dose-related in trials. Heart rate increases were noted with retatrutide. These remain investigational or approved agents with specific indications; individual responses differ and monitoring by a clinician is required in any real-world use.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/retatrutide-tirzepatide/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Retatrutide 12 mg produced mean 24.2% weight loss at 48 weeks in phase 2 obesity trial versus 2.1% placebo.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Quantifies human trial weight loss magnitude for load-reduction context.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:50:01.610Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Tirzepatide 15 mg produced mean 20.9% weight loss at 72 weeks in SURMOUNT-1 versus 3.1% placebo.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Provides parallel human trial benchmark for comparison.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:50:01.610Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Each additional pound of body weight adds approximately 4 lb compressive force to the lumbar spine during walking.","section":"What's breaking down","tier":"mechanistic","source_ids":[],"source_status":"unsourced","why_material":"Explains mechanical load layer targeted by weight-loss compounds.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:50:01.610Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Reddit users report personal weight losses of 50-100 lb on these compounds with variable appetite effects between them.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s3"],"source_status":"sourced","why_material":"Captures real-world user experience separate from trials.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:50:01.610Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2301972","title":"Triple–Hormone-Receptor Agonist Retatrutide for Obesity","quote":"At 48 weeks, the least-squares mean percentage change in the retatrutide groups was −8.7% in the 1-mg group, −17.1% in the combined 4-mg group, −22.8% in the combined 8-mg group, and −24.2% in the 12-mg group, as compared with −2.1% in the placebo group.","summary":"Phase 2 trial results for retatrutide weight loss.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:50:01.557Z","link_status":"http_403","quote_status":"unverified","prev":"genesis","hash":"6a1e25314940e55919f48e6ed0bd7442b9b451a64b0453402ba225e73b4669a0"},{"id":"s2","type":"pubmed","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2206038","title":"Tirzepatide Once Weekly for the Treatment of Obesity","quote":"the mean percentage change in weight at week 72 was −15.0% ... −19.5% ... and −20.9% ... and −3.1% ... with placebo","summary":"SURMOUNT-1 tirzepatide weight loss data.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:50:01.557Z","link_status":"http_403","quote_status":"unverified","prev":"6a1e25314940e55919f48e6ed0bd7442b9b451a64b0453402ba225e73b4669a0","hash":"b3088396a6ca6210794194b4c6f29d0203bcf760941674850291a1d5b462400f"},{"id":"s3","type":"reddit","url":"https://www.reddit.com/r/RetatrutideTrial/comments/1nwzgnd/tirzepatide_or_retatrutide/","title":"Tirzepatide or Retatrutide??","quote":"I lost 100 pounds with tirzepetide and am now maintaining with reta.","summary":"User anecdotes on switching and losses.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:50:01.557Z","link_status":"ok","quote_status":"unverified","prev":"b3088396a6ca6210794194b4c6f29d0203bcf760941674850291a1d5b462400f","hash":"b39e9694908231f84d5563a96281ea7b5b9abb75ff76a34bbbf91c2862a8c589"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-30T00:50:02.022Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"Retatrutide vs Tirzepatide: Human Trial Data on Weight Loss and Load Reduction","register":"source_ledger","body":"## What's breaking down\n\nExcess body weight increases compressive forces across the spine, hips, knees and feet. Each extra pound of body mass adds roughly 4 pounds of load to the lumbar spine during walking. When body weight stays elevated, mechanical stress outpaces natural repair in load-bearing tissues. Both compounds are studied for effects on body weight through GLP-1 and related pathways; any benefit to joints or spine would come from reduced load rather than direct tissue regeneration.\n\n## Why Retatrutide might help you\n\n1. What keeps failing: Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\n2. What Retatrutide is studied to do: Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\n3. Therefore for you: If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\n\n## Why Tirzepatide might help you\n\n1. What keeps failing: Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\n2. What Tirzepatide is studied to do: Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\n3. Therefore for you: If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\n\n## How these fit together\n\nEach compound above targets a different degeneration layer. Together they are a stack — not five copies of the same mechanism.\n- Retatrutide → metabolic load / body weight\n- Tirzepatide → metabolic load / body weight\n\n## What the evidence actually shows\n\nHuman phase 2 and phase 3 trials (human tier) show both compounds produce substantial weight loss. In one retatrutide trial, the 12 mg dose produced mean weight loss of 24.2% at 48 weeks versus 2.1% on placebo. In the SURMOUNT-1 tirzepatide trial, 15 mg produced mean weight loss of 20.9% at 72 weeks versus 3.1% on placebo. Later retatrutide phase 3 data (TRIUMPH-1) reported 28.3% mean loss at 80 weeks on 12 mg. These are percentage changes from baseline body weight in adults with obesity or overweight; results are dose-dependent and gastrointestinal side effects were common during escalation. No head-to-head trials exist yet. All data are from randomized controlled trials published in NEJM and company reports.\n\n## What scientists say\n\nPublished trial authors note the weight reductions exceed those seen with earlier GLP-1 agents and approach levels associated with bariatric surgery in some participants. Reductions in waist circumference, blood pressure and lipids were also observed alongside weight change. Researchers emphasize these are short-to-medium term findings (up to 104 weeks in extensions) and longer-term maintenance and safety data are still being collected.\n\n## What people say on Reddit\n\nAnecdotal reports (anecdotal tier) describe users switching between the two, with some noting stronger appetite suppression on tirzepatide and others preferring retatrutide for perceived energy or easier protein intake. Individual losses of 50–100 lb are mentioned after months of use, but experiences vary widely and many discuss side effects or dose titration challenges. These are self-reported posts from r/RetatrutideTrial, r/Mounjaro and similar communities.\n\n## What people say on X\n\nPublic posts on X are limited in the searched results; available mentions largely repeat trial headlines or user interest in upcoming approvals rather than detailed personal outcomes.\n\n## What we do not know\n\nDirect comparative efficacy, long-term joint or spine outcomes, effects on specific degenerative conditions, and durability of weight loss after discontinuation remain unknown. No human data link either compound to direct cartilage or disc repair independent of weight change.\n\n## Safety and limits\n\nBoth compounds show gastrointestinal adverse events that are mostly mild to moderate and dose-related in trials. Heart rate increases were noted with retatrutide. These remain investigational or approved agents with specific indications; individual responses differ and monitoring by a clinician is required in any real-world use.","claims":[{"id":"c1","text":"Retatrutide 12 mg produced mean 24.2% weight loss at 48 weeks in phase 2 obesity trial versus 2.1% placebo.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Quantifies human trial weight loss magnitude for load-reduction context.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:50:01.610Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Tirzepatide 15 mg produced mean 20.9% weight loss at 72 weeks in SURMOUNT-1 versus 3.1% placebo.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Provides parallel human trial benchmark for comparison.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:50:01.610Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Each additional pound of body weight adds approximately 4 lb compressive force to the lumbar spine during walking.","section":"What's breaking down","tier":"mechanistic","source_ids":[],"source_status":"unsourced","why_material":"Explains mechanical load layer targeted by weight-loss compounds.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:50:01.610Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Reddit users report personal weight losses of 50-100 lb on these compounds with variable appetite effects between them.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s3"],"source_status":"sourced","why_material":"Captures real-world user experience separate from trials.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:50:01.610Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2301972","title":"Triple–Hormone-Receptor Agonist Retatrutide for Obesity","quote":"At 48 weeks, the least-squares mean percentage change in the retatrutide groups was −8.7% in the 1-mg group, −17.1% in the combined 4-mg group, −22.8% in the combined 8-mg group, and −24.2% in the 12-mg group, as compared with −2.1% in the placebo group.","link_status":"http_403","quote_status":"unverified"},{"id":"s2","type":"pubmed","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2206038","title":"Tirzepatide Once Weekly for the Treatment of Obesity","quote":"the mean percentage change in weight at week 72 was −15.0% ... −19.5% ... and −20.9% ... and −3.1% ... with placebo","link_status":"http_403","quote_status":"unverified"},{"id":"s3","type":"reddit","url":"https://www.reddit.com/r/RetatrutideTrial/comments/1nwzgnd/tirzepatide_or_retatrutide/","title":"Tirzepatide or Retatrutide??","quote":"I lost 100 pounds with tirzepetide and am now maintaining with reta.","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":17431,"tokens_out":2707,"cost":0.02855625,"prev_hash":"genesis","hash":"92265659b24fb1f01609c41eb79e71a4e8f01c5b238822ae53c197d1dacd33eb"}],"provenance":[{"ts":"2026-06-30T00:50:02.022Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Retatrutide for Tirzepatide\nSlug: retatrutide-tirzepatide\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"dual_compound\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"retatrutide\",\"name\":\"Retatrutide\"},{\"id\":\"tirzepatide\",\"name\":\"Tirzepatide\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"retatrutide\",\"name\":\"Retatrutide\",\"section_title\":\"Why Retatrutide might help you\",\"layer\":\"metabolic load / body weight\",\"steps\":[\"**What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\",\"**What Retatrutide is studied to do:** Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\",\"**Therefore for you:** If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\\n2. **What Retatrutide is studied to do:** Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\\n3. **Therefore for you:** If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — ","response":"{\n  \"slug\": \"retatrutide-tirzepatide\",\n  \"title\": \"Retatrutide vs Tirzepatide: Human Trial Data on Weight Loss and Load Reduction\",\n  \"body\": \"## What's breaking down\\n\\nExcess body weight increases compressive forces across the spine, hips, knees and feet. Each extra pound of body mass adds roughly 4 pounds of load to the lumbar spine during walking. When body weight stays elevated, mechanical stress outpaces natural repair in load-bearing tissues. Both compounds are studied for effects on body weight through GLP-1 and related pathways; any benefit to joints or spine would come from reduced load rather than direct tissue regeneration.\\n\\n## Why Retatrutide might help you\\n\\n1. What keeps failing: Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\\n2. What Retatrutide is studied to do: Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\\n3. Therefore for you: If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\\n\\n## Why Tirzepatide might help you\\n\\n1. What keeps failing: Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\\n2. What Tirzepatide is studied to do: Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\\n3. Therefore for you: If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\\n\\n## How these fit together\\n\\nEach compound above targets a different degeneration layer. Together they are a stack — not five copies of the same mechanism.\\n- Retatrutide → metabolic load / body weight\\n- Tirzepatide → metabolic load / body weight\\n\\n## What the evidence actually shows\\n\\nHuman phase 2 and phase 3 trials (human tier) show both compounds produce substantial weight loss. In one retatrutide trial, the 12 mg dose produced mean weight loss o","tokens_in":17431,"tokens_out":2707,"cost":0,"prev":"genesis","hash":"dcd5b77ea49b50710f08fd37f5100db86cc5693255f4dcbb229b99841ceaee7a"},{"ts":"2026-07-17T02:41:22.042Z","model":"owner","action":"voxel_divide","prompt":"","input":"retatrutide-tirzepatide","response":"21 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"dcd5b77ea49b50710f08fd37f5100db86cc5693255f4dcbb229b99841ceaee7a","hash":"55042951126723480abe235b11b34cba9bfa355e9afaadb2184fd1785e034f1a"}],"energy":{"passes":2,"tokens_in":17431,"tokens_out":2707,"tokens_total":20138,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"55042951126723480abe235b11b34cba9bfa355e9afaadb2184fd1785e034f1a"},"posted_at":"2026-06-29T21:33:02.737Z","created_at":"2026-06-29T21:33:02.737Z","updated_at":"2026-07-17T02:41:22.042Z","machine":{"shape":"article.machine/v1","slug":"retatrutide-tirzepatide","kind":"article","read":{"human":"https://miscsubjects.com/a/retatrutide-tirzepatide","json":"https://miscsubjects.com/api/articles/retatrutide-tirzepatide","bundle":"https://miscsubjects.com/api/articles/retatrutide-tirzepatide/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":4,"sources":3,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/retatrutide-tirzepatide/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=retatrutide-tirzepatide","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"retatrutide-tirzepatide\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"retatrutide-tirzepatide\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/retatrutide-tirzepatide/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"retatrutide-tirzepatide\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/retatrutide-tirzepatide | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/retatrutide-tirzepatide","json":"/api/articles/retatrutide-tirzepatide","markdown":"/api/articles/retatrutide-tirzepatide/bundle?format=markdown","skill":"/api/articles/retatrutide-tirzepatide/skill","topology":"/api/articles/retatrutide-tirzepatide/topology","versions":"/api/articles/retatrutide-tirzepatide/revisions","invocations":"/api/articles/retatrutide-tirzepatide/invocations"},"editorial_review":null,"editorial_audit":{"slug":"retatrutide-tirzepatide","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"ef2fff522945035451eaea792ec9d0978f6e115caa6083a328800481b98fb871","object":{"object_type":"article-object","identity":{"id":"article:retatrutide-tirzepatide","slug":"retatrutide-tirzepatide","title":"Retatrutide vs Tirzepatide: Human Trial Data on Weight Loss and Load Reduction"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/retatrutide-tirzepatide","role":"explain","audience":"human"},"skill":{"route":"/api/articles/retatrutide-tirzepatide/skill","role":"direct behavior","audience":"model","content":"---\nname: retatrutide-tirzepatide\ndescription: Apply the Retatrutide vs Tirzepatide: Human Trial Data on Weight Loss and Load Reduction article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# Retatrutide vs Tirzepatide: Human Trial Data on Weight Loss and Load Reduction\n\nThis Skill is the behavioral expression of [the canonical article](/a/retatrutide-tirzepatide). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/retatrutide-tirzepatide.\n- Read claims and relationships at /api/articles/retatrutide-tirzepatide/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down Excess body weight increases compressive forces across the spine, hips, knees and feet. Each extra pound of body mass adds roughly 4 pounds of load to the lumbar spine during walking. When body weight stays elevated, me\n\n## Representations\n\n- Human: /a/retatrutide-tirzepatide\n- JSON: /api/articles/retatrutide-tirzepatide\n- Relationships: /api/articles/retatrutide-tirzepatide/topology\n- History: /api/articles/retatrutide-tirzepatide/revisions\n"},"json":{"route":"/api/articles/retatrutide-tirzepatide","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/retatrutide-tirzepatide/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","retatrutide","tirzepatide"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/retatrutide-tirzepatide/invocations?status=success","failure_events":"/api/articles/retatrutide-tirzepatide/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"retatrutide-tirzepatide","title":"Retatrutide vs Tirzepatide: Human Trial Data on Weight Loss and Load Reduction","body":"## What's breaking down\n\nExcess body weight increases compressive forces across the spine, hips, knees and feet. Each extra pound of body mass adds roughly 4 pounds of load to the lumbar spine during walking. When body weight stays elevated, mechanical stress outpaces natural repair in load-bearing tissues. Both compounds are studied for effects on body weight through GLP-1 and related pathways; any benefit to joints or spine would come from reduced load rather than direct tissue regeneration.\n\n## Why Retatrutide might help you\n\n1. What keeps failing: Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\n2. What Retatrutide is studied to do: Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\n3. Therefore for you: If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\n\n## Why Tirzepatide might help you\n\n1. What keeps failing: Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\n2. What Tirzepatide is studied to do: Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\n3. Therefore for you: If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\n\n## How these fit together\n\nEach compound above targets a different degeneration layer. Together they are a stack — not five copies of the same mechanism.\n- Retatrutide → metabolic load / body weight\n- Tirzepatide → metabolic load / body weight\n\n## What the evidence actually shows\n\nHuman phase 2 and phase 3 trials (human tier) show both compounds produce substantial weight loss. In one retatrutide trial, the 12 mg dose produced mean weight loss of 24.2% at 48 weeks versus 2.1% on placebo. In the SURMOUNT-1 tirzepatide trial, 15 mg produced mean weight loss of 20.9% at 72 weeks versus 3.1% on placebo. Later retatrutide phase 3 data (TRIUMPH-1) reported 28.3% mean loss at 80 weeks on 12 mg. These are percentage changes from baseline body weight in adults with obesity or overweight; results are dose-dependent and gastrointestinal side effects were common during escalation. No head-to-head trials exist yet. All data are from randomized controlled trials published in NEJM and company reports.\n\n## What scientists say\n\nPublished trial authors note the weight reductions exceed those seen with earlier GLP-1 agents and approach levels associated with bariatric surgery in some participants. Reductions in waist circumference, blood pressure and lipids were also observed alongside weight change. Researchers emphasize these are short-to-medium term findings (up to 104 weeks in extensions) and longer-term maintenance and safety data are still being collected.\n\n## What people say on Reddit\n\nAnecdotal reports (anecdotal tier) describe users switching between the two, with some noting stronger appetite suppression on tirzepatide and others preferring retatrutide for perceived energy or easier protein intake. Individual losses of 50–100 lb are mentioned after months of use, but experiences vary widely and many discuss side effects or dose titration challenges. These are self-reported posts from r/RetatrutideTrial, r/Mounjaro and similar communities.\n\n## What people say on X\n\nPublic posts on X are limited in the searched results; available mentions largely repeat trial headlines or user interest in upcoming approvals rather than detailed personal outcomes.\n\n## What we do not know\n\nDirect comparative efficacy, long-term joint or spine outcomes, effects on specific degenerative conditions, and durability of weight loss after discontinuation remain unknown. No human data link either compound to direct cartilage or disc repair independent of weight change.\n\n## Safety and limits\n\nBoth compounds show gastrointestinal adverse events that are mostly mild to moderate and dose-related in trials. Heart rate increases were noted with retatrutide. These remain investigational or approved agents with specific indications; individual responses differ and monitoring by a clinician is required in any real-world use.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/retatrutide-tirzepatide/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Retatrutide 12 mg produced mean 24.2% weight loss at 48 weeks in phase 2 obesity trial versus 2.1% placebo.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Quantifies human trial weight loss magnitude for load-reduction context.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:50:01.610Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Tirzepatide 15 mg produced mean 20.9% weight loss at 72 weeks in SURMOUNT-1 versus 3.1% placebo.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Provides parallel human trial benchmark for comparison.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:50:01.610Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Each additional pound of body weight adds approximately 4 lb compressive force to the lumbar spine during walking.","section":"What's breaking down","tier":"mechanistic","source_ids":[],"source_status":"unsourced","why_material":"Explains mechanical load layer targeted by weight-loss compounds.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:50:01.610Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Reddit users report personal weight losses of 50-100 lb on these compounds with variable appetite effects between them.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s3"],"source_status":"sourced","why_material":"Captures real-world user experience separate from trials.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:50:01.610Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2301972","title":"Triple–Hormone-Receptor Agonist Retatrutide for Obesity","quote":"At 48 weeks, the least-squares mean percentage change in the retatrutide groups was −8.7% in the 1-mg group, −17.1% in the combined 4-mg group, −22.8% in the combined 8-mg group, and −24.2% in the 12-mg group, as compared with −2.1% in the placebo group.","summary":"Phase 2 trial results for retatrutide weight loss.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:50:01.557Z","link_status":"http_403","quote_status":"unverified","prev":"genesis","hash":"6a1e25314940e55919f48e6ed0bd7442b9b451a64b0453402ba225e73b4669a0"},{"id":"s2","type":"pubmed","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2206038","title":"Tirzepatide Once Weekly for the Treatment of Obesity","quote":"the mean percentage change in weight at week 72 was −15.0% ... −19.5% ... and −20.9% ... and −3.1% ... with placebo","summary":"SURMOUNT-1 tirzepatide weight loss data.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:50:01.557Z","link_status":"http_403","quote_status":"unverified","prev":"6a1e25314940e55919f48e6ed0bd7442b9b451a64b0453402ba225e73b4669a0","hash":"b3088396a6ca6210794194b4c6f29d0203bcf760941674850291a1d5b462400f"},{"id":"s3","type":"reddit","url":"https://www.reddit.com/r/RetatrutideTrial/comments/1nwzgnd/tirzepatide_or_retatrutide/","title":"Tirzepatide or Retatrutide??","quote":"I lost 100 pounds with tirzepetide and am now maintaining with reta.","summary":"User anecdotes on switching and losses.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:50:01.557Z","link_status":"ok","quote_status":"unverified","prev":"b3088396a6ca6210794194b4c6f29d0203bcf760941674850291a1d5b462400f","hash":"b39e9694908231f84d5563a96281ea7b5b9abb75ff76a34bbbf91c2862a8c589"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-30T00:50:02.022Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"Retatrutide vs Tirzepatide: Human Trial Data on Weight Loss and Load Reduction","register":"source_ledger","body":"## What's breaking down\n\nExcess body weight increases compressive forces across the spine, hips, knees and feet. Each extra pound of body mass adds roughly 4 pounds of load to the lumbar spine during walking. When body weight stays elevated, mechanical stress outpaces natural repair in load-bearing tissues. Both compounds are studied for effects on body weight through GLP-1 and related pathways; any benefit to joints or spine would come from reduced load rather than direct tissue regeneration.\n\n## Why Retatrutide might help you\n\n1. What keeps failing: Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\n2. What Retatrutide is studied to do: Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\n3. Therefore for you: If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\n\n## Why Tirzepatide might help you\n\n1. What keeps failing: Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\n2. What Tirzepatide is studied to do: Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\n3. Therefore for you: If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\n\n## How these fit together\n\nEach compound above targets a different degeneration layer. Together they are a stack — not five copies of the same mechanism.\n- Retatrutide → metabolic load / body weight\n- Tirzepatide → metabolic load / body weight\n\n## What the evidence actually shows\n\nHuman phase 2 and phase 3 trials (human tier) show both compounds produce substantial weight loss. In one retatrutide trial, the 12 mg dose produced mean weight loss of 24.2% at 48 weeks versus 2.1% on placebo. In the SURMOUNT-1 tirzepatide trial, 15 mg produced mean weight loss of 20.9% at 72 weeks versus 3.1% on placebo. Later retatrutide phase 3 data (TRIUMPH-1) reported 28.3% mean loss at 80 weeks on 12 mg. These are percentage changes from baseline body weight in adults with obesity or overweight; results are dose-dependent and gastrointestinal side effects were common during escalation. No head-to-head trials exist yet. All data are from randomized controlled trials published in NEJM and company reports.\n\n## What scientists say\n\nPublished trial authors note the weight reductions exceed those seen with earlier GLP-1 agents and approach levels associated with bariatric surgery in some participants. Reductions in waist circumference, blood pressure and lipids were also observed alongside weight change. Researchers emphasize these are short-to-medium term findings (up to 104 weeks in extensions) and longer-term maintenance and safety data are still being collected.\n\n## What people say on Reddit\n\nAnecdotal reports (anecdotal tier) describe users switching between the two, with some noting stronger appetite suppression on tirzepatide and others preferring retatrutide for perceived energy or easier protein intake. Individual losses of 50–100 lb are mentioned after months of use, but experiences vary widely and many discuss side effects or dose titration challenges. These are self-reported posts from r/RetatrutideTrial, r/Mounjaro and similar communities.\n\n## What people say on X\n\nPublic posts on X are limited in the searched results; available mentions largely repeat trial headlines or user interest in upcoming approvals rather than detailed personal outcomes.\n\n## What we do not know\n\nDirect comparative efficacy, long-term joint or spine outcomes, effects on specific degenerative conditions, and durability of weight loss after discontinuation remain unknown. No human data link either compound to direct cartilage or disc repair independent of weight change.\n\n## Safety and limits\n\nBoth compounds show gastrointestinal adverse events that are mostly mild to moderate and dose-related in trials. Heart rate increases were noted with retatrutide. These remain investigational or approved agents with specific indications; individual responses differ and monitoring by a clinician is required in any real-world use.","claims":[{"id":"c1","text":"Retatrutide 12 mg produced mean 24.2% weight loss at 48 weeks in phase 2 obesity trial versus 2.1% placebo.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Quantifies human trial weight loss magnitude for load-reduction context.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:50:01.610Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Tirzepatide 15 mg produced mean 20.9% weight loss at 72 weeks in SURMOUNT-1 versus 3.1% placebo.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Provides parallel human trial benchmark for comparison.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:50:01.610Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Each additional pound of body weight adds approximately 4 lb compressive force to the lumbar spine during walking.","section":"What's breaking down","tier":"mechanistic","source_ids":[],"source_status":"unsourced","why_material":"Explains mechanical load layer targeted by weight-loss compounds.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:50:01.610Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Reddit users report personal weight losses of 50-100 lb on these compounds with variable appetite effects between them.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s3"],"source_status":"sourced","why_material":"Captures real-world user experience separate from trials.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:50:01.610Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2301972","title":"Triple–Hormone-Receptor Agonist Retatrutide for Obesity","quote":"At 48 weeks, the least-squares mean percentage change in the retatrutide groups was −8.7% in the 1-mg group, −17.1% in the combined 4-mg group, −22.8% in the combined 8-mg group, and −24.2% in the 12-mg group, as compared with −2.1% in the placebo group.","link_status":"http_403","quote_status":"unverified"},{"id":"s2","type":"pubmed","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2206038","title":"Tirzepatide Once Weekly for the Treatment of Obesity","quote":"the mean percentage change in weight at week 72 was −15.0% ... −19.5% ... and −20.9% ... and −3.1% ... with placebo","link_status":"http_403","quote_status":"unverified"},{"id":"s3","type":"reddit","url":"https://www.reddit.com/r/RetatrutideTrial/comments/1nwzgnd/tirzepatide_or_retatrutide/","title":"Tirzepatide or Retatrutide??","quote":"I lost 100 pounds with tirzepetide and am now maintaining with reta.","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":17431,"tokens_out":2707,"cost":0.02855625,"prev_hash":"genesis","hash":"92265659b24fb1f01609c41eb79e71a4e8f01c5b238822ae53c197d1dacd33eb"}],"provenance":[{"ts":"2026-06-30T00:50:02.022Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Retatrutide for Tirzepatide\nSlug: retatrutide-tirzepatide\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"dual_compound\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"retatrutide\",\"name\":\"Retatrutide\"},{\"id\":\"tirzepatide\",\"name\":\"Tirzepatide\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"retatrutide\",\"name\":\"Retatrutide\",\"section_title\":\"Why Retatrutide might help you\",\"layer\":\"metabolic load / body weight\",\"steps\":[\"**What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\",\"**What Retatrutide is studied to do:** Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\",\"**Therefore for you:** If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\\n2. **What Retatrutide is studied to do:** Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\\n3. **Therefore for you:** If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — ","response":"{\n  \"slug\": \"retatrutide-tirzepatide\",\n  \"title\": \"Retatrutide vs Tirzepatide: Human Trial Data on Weight Loss and Load Reduction\",\n  \"body\": \"## What's breaking down\\n\\nExcess body weight increases compressive forces across the spine, hips, knees and feet. Each extra pound of body mass adds roughly 4 pounds of load to the lumbar spine during walking. When body weight stays elevated, mechanical stress outpaces natural repair in load-bearing tissues. Both compounds are studied for effects on body weight through GLP-1 and related pathways; any benefit to joints or spine would come from reduced load rather than direct tissue regeneration.\\n\\n## Why Retatrutide might help you\\n\\n1. What keeps failing: Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\\n2. What Retatrutide is studied to do: Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\\n3. Therefore for you: If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\\n\\n## Why Tirzepatide might help you\\n\\n1. What keeps failing: Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\\n2. What Tirzepatide is studied to do: Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\\n3. Therefore for you: If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\\n\\n## How these fit together\\n\\nEach compound above targets a different degeneration layer. Together they are a stack — not five copies of the same mechanism.\\n- Retatrutide → metabolic load / body weight\\n- Tirzepatide → metabolic load / body weight\\n\\n## What the evidence actually shows\\n\\nHuman phase 2 and phase 3 trials (human tier) show both compounds produce substantial weight loss. In one retatrutide trial, the 12 mg dose produced mean weight loss o","tokens_in":17431,"tokens_out":2707,"cost":0,"prev":"genesis","hash":"dcd5b77ea49b50710f08fd37f5100db86cc5693255f4dcbb229b99841ceaee7a"},{"ts":"2026-07-17T02:41:22.042Z","model":"owner","action":"voxel_divide","prompt":"","input":"retatrutide-tirzepatide","response":"21 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"dcd5b77ea49b50710f08fd37f5100db86cc5693255f4dcbb229b99841ceaee7a","hash":"55042951126723480abe235b11b34cba9bfa355e9afaadb2184fd1785e034f1a"}],"energy":{"passes":2,"tokens_in":17431,"tokens_out":2707,"tokens_total":20138,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"55042951126723480abe235b11b34cba9bfa355e9afaadb2184fd1785e034f1a"},"posted_at":"2026-06-29T21:33:02.737Z","created_at":"2026-06-29T21:33:02.737Z","updated_at":"2026-07-17T02:41:22.042Z","machine":{"shape":"article.machine/v1","slug":"retatrutide-tirzepatide","kind":"article","read":{"human":"https://miscsubjects.com/a/retatrutide-tirzepatide","json":"https://miscsubjects.com/api/articles/retatrutide-tirzepatide","bundle":"https://miscsubjects.com/api/articles/retatrutide-tirzepatide/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":4,"sources":3,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/retatrutide-tirzepatide/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=retatrutide-tirzepatide","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"retatrutide-tirzepatide\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"retatrutide-tirzepatide\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/retatrutide-tirzepatide/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"retatrutide-tirzepatide\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/retatrutide-tirzepatide | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/retatrutide-tirzepatide","json":"/api/articles/retatrutide-tirzepatide","markdown":"/api/articles/retatrutide-tirzepatide/bundle?format=markdown","skill":"/api/articles/retatrutide-tirzepatide/skill","topology":"/api/articles/retatrutide-tirzepatide/topology","versions":"/api/articles/retatrutide-tirzepatide/revisions","invocations":"/api/articles/retatrutide-tirzepatide/invocations"},"editorial_review":null,"editorial_audit":{"slug":"retatrutide-tirzepatide","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"ef2fff522945035451eaea792ec9d0978f6e115caa6083a328800481b98fb871"}}}